This page lists all pharmaceutical reports related to the field of Psychiatric, Addictive & Sleep Disorders. The reports include market research reports and pipeline analyses.
Displaying 51 - 100 of 113 results
- Two pharmaceutical reports for the price of one - End of year offer
- UpdatesPlus Nicotinic Receptors - Current Research and Development - February 2009
- Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
- Smoking Cessation Report, 2009-2024
- UpdatesPlus Nicotinic Receptors - Current Research and Development - March 2009
- New Approaches to Pharma Research and Development: Evolving strategies to rejuvenate Research and Development efficiency
- UpdatesPlus Nicotinic Receptors - Current Research and Development - June 2009
- UpdatesPlus Nicotinic Receptors - Current Research and Development - July 2009
- World Sleep Disorders Market Analysis 2009-2024
- UpdatesPlus Nicotinic Receptors - Current Research and Development - September 2009
- Monoclonal Antibody Therapeutics 2009-2024
- World Generics Market 2009-2024
- The World Market for Biosimilars and the Potential for US Follow-on Biologics
- Global Pharmaceutical Biotech Market 2010-2025
- What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and Other Vaccine Targets in the 2010-2020 Pipeline
- World Smoking-Cessation Drug Market 2010-2025
- The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
- The Future of Orphan Disease Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
- Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline
- Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
- Insomnia - Drug Pipeline Analysis and Market Forecasts to 2015
- Schizophrenia - Drug Pipeline Analysis and Market Forecasts to 2015
- Bipolar Disorder - Drug Pipeline Analysis and Market Forecasts to 2015
- Addiction Control - Drug Pipeline Analysis and Market Forecasts to 2015
- World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)
- Neurology Devices Market Outlook in United States to 2016 - Neurostimulation Devices, Interventional Neurology and Others
- Neurology Devices Market Outlook in Japan to 2016 - Neurostimulation Devices, Interventional Neurology and Others
- CNS Clinical Trials: World Market Prospects 2011-2026
- US Pharmaceutical Market Outlook 2011-2021
- Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions
- UpdatesPlus Nicotinic Receptors - Current Research and Development - March 2011
- R&D Trends: Depression
- Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
- Pharmaceutical Key Trends 2011 – Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits
- R&D Trends: Depression - Pipeline characterized by its depth and diversity
- R&D Trends: Bipolar Disorders - Developments in schizophrenia dictate trends in diminutive bipolar disorders pipeline
- UpdatesPlus Nicotinic Receptors and Addiction - Current Research and Development - April/May 2011
- Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
- Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
- Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
- Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure
- Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
- Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies
- Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
- Latuda (Schizophrenia) – Analysis and Forecasts to 2020
- undefinedInvega (Schizophrenia) – Analysis and Forecasts to 2020
- Saphris (Schizophrenia) – Analysis and Forecasts to 2020
- Zicronapine (Schizophrenia) – Analysis and Forecasts to 2020
- Geodon (Schizophrenia) – Analysis and Forecasts to 2017
- Clozapine (Schizophrenia) – Analysis and Forecasts to 2020